The otc drug and dietary supplement market has seen considerable growth due to a variety of factors.
•Recent years have seen robust growth in the market size of OTC drug and dietary supplements. By 2024, this market is predicted to be worth $332.52 billion and is expected to appreciate to $355.94 billion in 2025, due to a compound annual growth rate (CAGR) of 7.0%.
The impressive growth during the historical period can be traced back to various factors like a surge in fitness enthusiasts, demographic transitions, an increasingly aging population, regulatory sanctions and safety standards, expansion of pharmacies and retail, coupled with effective marketing and advertising strategies.
The otc drug and dietary supplement market is expected to maintain its strong growth trajectory in upcoming years.
• The market size of OTC drugs and dietary supplements is projected to witness significant escalation in the coming years, reaching a value of $470.7 billion by 2029, growing at a compound annual growth rate (CAGR) of 7.2%.
The expected growth during the forecasted timeframe can be ascribed to factors such as custom-fit nutrition and supplements, advancements in nutraceuticals, the expansion of beneficial food products, global health uncertainties and readiness, and wellness-oriented government initiatives. Some of the major trends expected during this period include innovative products, unambiguous and organic ingredients, CBD and hemp-driven products, environmentally sustainable packaging, plus strategic partnerships and collaborations.
The future growth of the OTC drug and dietary supplement market is foreseen to be propelled by an increase in pharmaceutical research and development (R&D) expenses. R&D investment, which refers to a company's expenditure for the creation, enhancement, and improvement of its products, can stimulate creativity and efficiency in the development and formulation of OTC drugs and dietary supplements. For example, Eurostat, the Luxembourg-based statistical bureau of the European Union, reported in December 2023 that the EU's R&D spending surged to €352 billion ($384.42 billion) in 2022. This represents a 6.34% increase from the €331 billion ($361.48 billion) spent the prior year. Hence, the boost in pharmaceutical R&D expenses is a significant driver of the OTC drug and dietary supplement market.
The OTC drug and dietary supplement market covered in this report is segmented –
1) By Category: Vitamin And Dietary Supplements, Cough And Cold Products, Analgesics, Gastrointestinal Products, Sleep Aids, Otic Products, Wart Removers, Mouth Care Products, Ophthalmic Products, Other Categories
2) By Dosage Form: Tablets, Hard Capsules, Powders, Ointments, Soft Capsules, Liquids, Other Dosage Forms
3) By Application: Pharmacies, Grocery Stores, Vitamin And Health Food Stores, Online Pharmacies
Subsegments:
1) By Vitamin And Dietary Supplements: Multivitamins, Mineral Supplements, Herbal Supplements, Omega-3 Fatty Acids, Probiotics, Specialty Supplements
2) By Cough And Cold Products: Cough Suppressants, Expectorants, Decongestants, Combination Products
3) By Analgesics: Acetaminophen, NSAIDs, Topical Analgesics
4) By Gastrointestinal Products: Antacids, Laxatives, Antidiarrheals, Proton Pump Inhibitors
5) By Sleep Aids: Melatonin, Antihistamines, Herbal Sleep Aids
6) By Otic Products: Ear Wax Removal Aids, Ear Drops For Infections, Anti-itch Ear Products
7) By Wart Removers: Salicylic Acid Products, Cryotherapy Kits
8) By Mouth Care Products: Mouthwashes, Toothpastes, Oral Rinses For Freshness
9) By Ophthalmic Products: Artificial Tears, Allergy Eye Drops, Redness Relievers
10) By Other Categories: Nutraceuticals, Topical Treatments For Skin Conditions, First Aid Products
Pioneering new products is a prime trend that's quickly gaining traction in the over-the-counter (OTC) drug and dietary supplement industry. To consolidate their market presence, large corporations in the OTC drug and dietary supplement sector are focusing on creating unique offerings. For example, in July 2022, Dr. Reddy’s Laboratories Ltd., a pharmaceutical company from India, introduced to the market their new products Fexofenadine HCl 180 mg and Pseudoephedrine HCl 240 mg extended-release tablets. Sold over-the-counter, these are oral antihistamines and nasal decongestants used for temporary amelioration of nasal and sinus congestion caused by colds or allergies, thus being a significant enhancement to their existing lineup of upper respiratory OTC items.
Major companies operating in the OTC drug and dietary supplement market include:
• Pfizer Inc.
• Johnson & Johnson Ltd.
• Merck & Co. Inc.
• Bayer AG
• Novartis AG
• Sanofi S.A
• Abbott Laboratories Inc
• GSK plc
• Gilead Sciences Inc.
• Reckitt Benckiser Plc.
• Teva Pharmaceutical Industries Ltd.
• Alcon Inc.
• Bausch Health Companies Inc.
• Sun Pharmaceutical Industries Ltd.
• Church & Dwight Co Inc
• Perrigo Company plc
• Dr. Reddy's Laboratories Ltd.
• Cipla Limited
• Glenmark Pharmaceuticals Limited
• Alkem Laboratories Ltd
• Nutraceutical International Corporation
• Procter & Gamble Health Limited
• Reese Pharmaceutical Company
• UPM Pharmaceuticals Inc
• Gemini Pharmaceuticals Inc.
• Pharmavite LLC
• Now Health Group Inc.
• Alfresa Pharma Corporation
North America was the largest region in the OTC drug and dietary supplement market in 2024. The regions covered in the OTC drug and dietary supplement market report are Asia-Pacific, Western Europe, Eastern Europe, North America, South America, Middle East, Africa.